Aclarion enters second commercial agreement with Weill Cornell Medicine

Aclarion (ACON) announced it has established a second commercial agreement with Weill Cornell Medicine. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center through a trial led by renowned neurosurgeon, Roger Hartl, MD, the founder and director of the Weill Cornell Medicine Center for Comprehensive Spine Care and co-director of Och Spine at NewYork-Presbyterian. The trial is entitled “Bone Marrow Aspirate Concentrate Injection with MRI’s – a Prospective Randomized Controlled Trial,” conducted under IRB Protocol No. 24-09027977. The purpose of this study is to evaluate the long-term effects of lumbar microdiscectomy surgery with and without an intradiscal bone marrow aspirate concentrate injection on patient reported outcomes, intervertebral disc health, and pain biomarkers in a 2-year prospective study. The aim is to learn more about the natural history of degenerative disc disease, its causes, and inform its treatments.